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Role of intron 1 in smooth muscle a-actin transcriptional regu- Mesangial hypercellularity and matrix expansion are
lation in activated mesangial cells in vivo. hallmarks of glomerular disease and play important roles
Background. The activation of glomerular mesangial cells in the progression of renal disease at late stages. There
is one of the early, important features of progressive glomerular
is increasing evidence that mesangial cells in glomerulardisease. Smooth muscle a-actin (SMaA) is an excellent marker
disease are activated and change to a secretory pheno-of activated mesangial cells. However, the mechanisms of
type [1–3]. Activated mesangial cells release inflamma-SMaA regulation are only available from in vitro investigation.
Methods. We examined in vivo promoter analysis of the tory mediators, cytokines, and growth factors and are
SMaA gene-utilizing transgenic mice harboring different pro- potent at producing extracellular matrix components.
moter regions of the SMaA gene fused to chloramphenicol Understanding the nature and mechanism of mesangial
acetyl transferase (CAT). CAT activities were tested in primary
cell activation may provide insight and novel therapeuticcultured mesangial cells and in glomerular legions of Habu
approaches toward progressive glomerular disease. Sev-venom glomerulonephritis.
eral molecular markers in activated mesangial cells areResults. The DNA sequence 2891 to 13828, which contains
exon 1, intron 1, and the first 14 bp of exon 2 in addition to reported. Enhanced expression of several contractile-
the 59-flanking sequence of the SMaA gene, induced high levels related proteins, such as caldesmon and SMemb, is one
of transcription in activated mesangial cells in in vivo habu feature of activated mesangial cells in vivo in both hu-
venom glomerulonephritis and in cultured mesangial cells de- mans and animals [4–7]; among these, smooth musclerived from transgenic mice. The DNA region 2891 to 2124
a-actin (SMaA) is the most widely recognized markerwas a positive element in mesangial cells derived from
of activated mesangial cells [8, 9].transgenic mice. Deletions (3316 or 137 bp) in intron 1 reduced
Smooth muscle a-actin is one of six actin isoformstranscription to undetectable levels. The 137 bp sequence is
highly conserved among several species, containing one CArG in mammals [10]. Under normal conditions, SMaA is
box element, which is one of the key motifs for transcriptional expressed exclusively and is the dominant protein in
activation of contractile-related proteins. In vitro transfection vascular and visceral smooth muscle cells [11, 12]. Nor-
analysis failed to demonstrate these positive effects of intron
mal glomeruli express only minimal SMaA; however,1 and region 2891 to 2124.
with progression to various forms of glomerular disease,Conclusions. In vivo promoter analysis of the SMaA gene
glomerular mesangial cells begin to express SMaA [8,provided new information about the transcriptional regulation
of SMaA in activated mesangial cells. The DNA region 2891 13–15]. Activated mesangial cells are also called myofi-
to 2124 has a positive effect on SMaA transcription in cultured broblast-like cells because of their extracellular matrix
mesangial cells. The intron 1 region (11088 to 11224) plays production and expression of contractile-related proteins
a pivotal role in SMaA transcription in activated mesangial [9]. Understanding the transcriptional regulation ofcells in vivo. Further analysis of this conserved region in intron
SMaA may provide an understanding of the phenotypic1, including the CArG motif, will be of great value in under-
modulations of mesangial cells to myofibroblast-likestanding the molecular mechanisms of mesangial activation.
cells.
Smooth muscle a-actin expression in smooth muscle
cells and in activated mesangial cells has been studiedKey words: myofibroblast, Habu venom glomerulonephritis, pheno-
typic modulation, CarG element, progressive renal disease. by in vitro transient transfection analysis. These studies
revealed the importance of the upstream region 2125Received for publication October 27, 1998
to 11 for expression of SMaA in both smooth muscleand in revised form January 6, 1999
Accepted for publication January 21, 1999 cells and activated mesangial cells [16–21]. This region
is called the “core promoter” and contains two CArG 1999 by the International Society of Nephrology
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box elements, which are designated as CArG #1 (262) sequence of the SMaA gene has been reported [18]. The
p123int-CAT, p891intDBH-CAT, and p891intD0-CATand CArG #2 (2112). Interaction of serum response
factor (SRF) with these two CArG boxes is characterized plasmids contain 2123 to 13828 of SMaA, 2891 to
13828 of SMaA with a 3.8 kb deletion in intron 1, andas one of the most important mechanisms for transcrip-
tional activation of SMaA. Recently, Hautmann, Mad- 2891 to 13828 of SMaA with a 137 bp deletion in intron
1, respectively (Fig. 1). These were subcloned 59 to thesen, and Owens described a novel transforming growth
factor-b (TGF-b) control element, 242 in this region CAT reporter gene in a modified pBluescript II KS (Stra-
tagene, La Jolla, CA, USA). p891-CAT and p123-CAT[22]. They also demonstrated that MHox, the murine
homologue of the homeodomain containing protein plasmids, which were used only for transient transfection
analysis, contain 2891 to 149 of SMaA and 2123 toPhox 1, can potentiate binding of SRF to CArG #2 [23,
24]. This new finding with regards to MHox, using in 149 of SMaA, respectively [18].
vitro transfection, enhances our understanding of the
Transgenic micemechanism of cell-specific transcription of the SMaA
gene. However, the problem with in vitro transfection Transgenic mice harboring the varying lengths of the
SMaA promoter regions, 891int-CAT, 123int-CAT, 891intanalysis of the “core promoter” region is that the “core
promoter” per se may not fully confer smooth muscle- DBH-CAT, and 891intD0-CAT, were generated on a
mixed C57BL/6 3 DBA/2 background according to stan-specific transcriptional activation of SMaA. Transcrip-
tional activities of a core promoter were reported in rat dard techniques [28]. To identify transgenic founder
mice, Southern blot analysis was performed with a radio-cultured skeletal myoblasts and in aortic endothelial cells
that do not express intrinsic SMaA [20]. To overcome labeled CAT probe (250 bp EcoRI fragment) and high
molecular weight DNA prepared from tail biopsies ofthis problem, positive and negative cis elements in loci
other than the core promoter region must be considered each potential founder. The number of copies per cell
was quantitated by comparing the hybridization signalas regulating cell type-specific transcriptional activation
of the SMaA gene [17, 20, 25–27]. We previously re- intensity to standards corresponding to 1, 5, 25, and 125
copies per cell with an image analyzer (BAS 1500 MAC;ported enhancer activity in intron 1 of the SMaA gene
[18], leading us to test the importance of intron 1, in Fuji-Rebio, Tokyo, Japan). Two independent founder
lines were identified in 891int-CAT, 123int-CAT, and 891addition to the core promoter and its upstream region,
in the transcriptional regulation of SMaA in the mesan- intD0-CAT transgenic mice, and three lines were identi-
fied in 891intDBH-CAT transgenic mice. The copy num-gial cell activation.
The goals of this study were to identify cis-acting DNA bers of transgenes of SMaA promoter transgenic mice
were 85, 120 (891int-CAT); 35, 90 (123int-CAT); 4, 8,regions within the human SMaA promoter that regulate
transcriptional activation of SMaA during in vivo activa- and 12 (891intDBH-CAT); and 35, 80 (891intD0-CAT).
tion of mesangial cells with glomerular disease. We used
Tissue preparationin vivo promoter analysis of SMaA in transgenic mice
harboring different promoter regions of SMaA. We For immunohistochemistry, mice were anesthetized
with pentobarbital and were perfused in situ with coldfound that the regulation of SMaA transcription is differ-
ent in cultured mesangial cells derived from transgenic phosphate-buffered saline to remove circulating blood
cells. Tissue sections from adult mice were immersed inmice compared with SMaA transcription in transiently
transfected wild-type mesangial cells. This study pro- a cold 4% paraformaldehyde solution or 70% ethanol
for 16 to 24 hours. After dehydration, tissues were em-vides new information about transcriptional regulation
of SMaA in activated mesangial cells. bedded in paraffin or Tissue-Tec O.T.C. compound
(Miles, Elkhart, IN, USA).
METHODS Cell culture
Promoter chloramphenicol acetyl transferase Mesangial cells were obtained by culturing glomeruli
expression plasmids isolated from kidneys of both transgenic and wild-type
BDF1 mice and were characterized as previously de-To identify regions that control the expression of the
SMaA gene in vivo, transgenic vectors were constructed scribed [29]. Cells were maintained in RPMI 1640 supple-
mented with 17% fetal calf serum (FCS), 100 U/ml peni-that encode the chloramphenicol acetyl transferase
(CAT) reporter gene under transcriptional control of cillin, and 100 mg/ml streptomycin at 378C in a humidified
atmosphere of 95% air and 5% CO2, with mediumSMaA promoter fragments. The p891int-CAT reporter
plasmid has a 4.7 kb fragment of the human SMaA gene, changes every three to four days. The first medium
change was performed seven days after explantation ofwhich contains the 59 upstream region, exon 1, intron 1,
and the first 14 bp of exon 2; this fragment contains glomeruli. Fourteen days after explantation, CAT assay,
CAT mRNA reverse transcription-polymerase chain re-2891 to 13828, followed by the CAT gene. The precise
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Fig. 1. Schematic representation of transgenes
used in this study. Abbreviations are: hSMaA,
human smooth muscle a-actin; CAT, chloram-
phenicol acetyl transferase.
action (RT-PCR) analysis, and CAT immunohistochem- Immunohistochemical study
istry were performed to test for transcriptional activation Smooth muscle a-actin and CAT proteins were identi-
of SMaA promoter fragments in cultured mesangial cells fied with anti-SMaA monoclonal antibody (1A4; Sigma
derived from transgenic mice. Co., St. Louis, MO, USA) and digoxigenated sheep anti-
CAT polyclonal antibody (Boehringer Mannheim GmbH,
Transient transfection analysis Mannheim, Germany). The anti-SMaA antibody was
For in vitro transient transfection analysis, mesangial biotinylated with a Biotin Protein Labeling Kit (Boeh-
cells at passages 5 to 7 from wild-type BDF1 mice were ringer Mannheim). Cultured cells or cryosections (10
employed. In preliminary experiments, we used cultured mm) obtained from tissues were fixed in 4% paraformal-
mesangial cells of earlier passages (2 to 3) for transient dehyde for 30 minutes and in ice-cold acetone for 30
transfection, but these cells did not survive as well as minutes. All sections were incubated in a 99:1 methanol/
cells of passages 5 to 7. Cells were seeded for transfection H2O2 solution for 30 minutes at room temperature to
assays into 6 cm dishes at a density of 4 3 104 cells/cm2. inactivate endogenous peroxidase activity. Primary anti-
These densities were chosen so that cells would be at bodies were then applied to the sections and incubated
80% confluence at the time of transfection (48 hr after for 16 hours at 48C. Sections for SMaA were then incu-
plating). Transient transfection experiments consisted of bated with an avidin-biotinylated horseradish peroxidase
transfecting each promoter-CAT plasmid in triplicate complex (Vector Laboratories, Burlingame, CA, USA)
using Lipofectamine Reagent (GIBCO BRL, Gaithers- for 40 minutes at room temperature. Peroxidase activity
burg, MD, USA) according to the manufacturer’s recom- was visualized with a solution containing 0.6 mg/ml of
mendation. Briefly, for each well to be transfected, 3 mg p-dimethyl aminobenzaldehyde and 10 mg/ml of H2O2
of a reporter gene construct and 1 mg of a luciferase in 50 mm Tris-HCl (pH 6.85) using DAB buffer tablets
reporter plasmid [pGV-P2; in 20 ml of 10 mm Tris (pH (Merck, Darmstadt, Germany). After counterstaining in
8.0), 1 mm ethylenediaminetetraacetic acid (EDTA)] methylgreen, sections were mounted.
were incubated for 30 minutes in a tissue culture-sterile Sections for CAT immunostaining were incubated
microcentrifuge tube with 20 ml of Lipofectamine Re- with the second antibody (peroxidase-conjugated sheep
agent and 600 ml of serum-free RPMI 1640. During the antidigoxigenin polyclonal antibody; Boehringer Mann-
incubation, each well was washed twice with 3 ml of heim) for 16 hours at 48C. After washing, TSAe-Indirect
transfection medium to remove residual serum, and after for Immunohistochemistry Renaissancee (Dupont/New
the second wash, 2.4 ml of fresh transfection medium England Nuclear, Boston, MA, USA) was used to inten-
and 600 ml of DNA/Lipofectamine/media solutions were sify CAT staining. Peroxidase activity was visualized as
added to each well. At four-hours post-transfection, 3 described earlier here, and counterstaining was per-
ml of RPMI 1640 supplemented with 17% FCS were formed. Negative controls used omission of the first anti-
added to each well. At 24-hours post-transfection, media body or substitution of normal mouse IgG for the anti-
were changed. After 48 hours in culture medium, cells SMaA monoclonal antibody or normal sheep serum for
anti-CAT polyclonal antibody.were harvested by scraping in buffer.
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Chloramphenicol acetyl transferase assay after a dorsolateral incision under pentobarbital anesthe-
sia. After a recovery period of 24 hours, lyophilizedMonolayers of mesangial cells were rinsed three times
venom from the Habu pit viper, Trimeresurus flavoviridiswith ice-cold phosphate-buffered saline and were incu-
(Wako Pure Chemical Industries, Osaka, Japan), wasbated for 15 minutes at room temperature with 400 ml
dissolved in saline and injected into a tail vein at a dosePicaGenee Cell Culture Lysis Reagent LCb (Toyo Inki
of 1.5 mg/kg body wt. Eight days after the infusion ofCo., Tokyo, Japan). Cells were then scraped off and
habu venom, the right kidney was removed. Kidney sec-collected by centrifugation for two minutes at 12,000 g.
tions were examined by immunohistochemistry.The supernatant was either assayed directly or stored
frozen at 2208C. The assay for CAT activity in cell ly-
sates was performed essentially as described [18] using RESULTS
[14C]-chloramphenicol (57 mCi/mmol; Amersham Co.,
Analysis of CAT transcription in transgenic mice
Buckinghamshire, UK) and equivalent amounts of cyto-
in vivo under normal conditions
plasmic extract. Acetylated products were separated by
To determine the significant promoter regions forthin-layer chromatography using MERCK Silica Gel 60
transcriptional regulation of SMaA in vivo in activatedF254 and exposed to MAC BAS IIIs (Fuji). The percent-
mesangial cells, varying lengths of the promoter regionage of conversion of [14C]-chloramphenicol to its ace-
were ligated to a CAT reporter gene; these transgenestylated derivatives was calculated by BAS 1500 MAC
were used for construction of transgenic mice (Fig. 1).(Fuji). Protein in cell lysates was measured by the Coo-
Figure 2 shows the representative appearance of CATmassie brilliant blue dye binding method with Bio-Rad
immunostaining in a normal glomerulus (Fig. 2 C, E,protein assay reagent using bovine g-globulin as a stan-
G, I) and abdominal aorta (Fig. 2 D, F, H, J) fromdard (BioRad, Hercules, CA, USA) [30]. In transient
transgenic mice. Endogenous SMaA expression wastransfection analysis, to account for possible differences
shown in kidney arterioles and the aortic media layerin transfection efficiency within the same experiment,
(Fig. 2 A, B). Expression of CAT in 891int-CAT (Fig.cells were cotransfected with pGV-P2, which directs lu-
2 C, D) and 123int-CAT (Fig. 2 E, F) transgenic miceciferase activity from the viral long-terminal repeat. Lu-
showed localization of CAT protein identical to that ofciferase activity in cell lysates was measured with a Pica-
endogenous SMaA. By contrast, partial removal of ei-Genee Luminescence Kit (Toyo Inki Co.).
ther large (3316 bp; Fig. 2 G, H) or small (137 bp; Fig.
Reverse transcription-polymerase chain reaction of 2 I, J) portions of intron 1 of the SMaA gene abolished
chloramphenicol acetyl transferase mRNA tissue-specific expression of CAT. These results demon-
strate that the region from 2123 to 13828 (containingTotal RNA of cultured mesangial cells was extracted
exon 1, intron 1, and the first 14 bp of exon 2) confersby an acid guanidinium thiocyanate-phenol-chloroform
smooth muscle-specific transcriptional activation ofextraction procedure using TRIzol reagent (GIBCO
SMaA in vivo. The 137 bp region in intron 1, especiallyBRL) according to the manufacturer’s instructions. Ex-
from 11088 to 11224, was also demonstrated to play antracted RNA was dissolved in sterile water, and contami-
important role in smooth muscle-specific expression ofnating DNA was digested with DNase I (GIBCO BRL).
SMaA. No detectable CAT expression was observed inReverse transcription was performed using the Gene-
the glomeruli of normal kidneys from transgenic mice.Amp RNA PCR Kit (Perkin-Elmer, Norwalk, CT, USA)
using 2.5 mg of total RNA as template, and oligo(dT)
Analysis of loci that control SMaA transcription inas a primer (428C 3 60 min and 958C 3 7 min) [31]. The
cultured mesangial cells derived from transgenic micecDNA was amplified by PCR using “SMA exon 1” (59-
Although mesangial cells in situ do not express detect-CTGTCAGGAATCCTGTGAAGC-39) and “CAT 1”
able amounts of SMaA, mesangial cells in culture ex-(59-AGTTGTCCATATTGGCCACG-39), which yielded
press substantial amounts of SMaA [32]. Mesangial cellsa 572 bp amplified product. A set of primers for glycer-
in culture are assumed to share the characteristics ofaldehyde-3-phosphate dehydrogenase (GAPDH; sense,
in vivo activated mesangial cells, as seen in glomerular59-TCCCTCAAGATTGTCAGCAA-39; antisense, 59-AG
disease, including SMaA expression. Thus, cultured mes-ATTCACAACGGATACATT-39; predicted product
angial cells are considered a good model of activationsize, 309 bp) was used as a control (25 cycles, 958C 3
[1, 9]. To investigate the effects of different promoterone min, 598C 3 one min, and 728C 3 one min). Samples
regions for induction of SMaA transcription in activatedwere analyzed by 1% agarose gel electrophoresis and
mesangial cells in culture, CAT immunostaining and en-stained with ethidium bromide.
zymatic activities were tested in mesangial cells derived
Habu snake venom-induced glomerulonephritis from transgenic mice harboring different SMaA pro-
moter regions. Figure 3 shows immunostaining of CATGlomerulonephritis (GN) was induced in six-week-
old male transgenic mice. The left kidneys were removed in primary cultured mesangial cells 14 days after the
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Fig. 2. Immunostaining for smooth muscle
a-actin (SMaA) and CAT in normal kidneys
(A, C, E, G, and I) and abdominal aorta (B,
D, F, H, and J) from transgenic mice. Sections
from 891int-CAT transgenic mice were used
for SMaA and CAT staining in glomerulus
(A and C) and in aorta (B and D). (A) SMaA
staining in normal kidney of 891int-CAT
transgenic mice. (C, E, G, I) CAT staining
in normal kidney of 891int-CAT (C), 123int-
CAT (E), 891intDBH-CAT (G), and 891int
D0-CAT (I) transgenic mice (original magni-
fication 3400). (B) SMaA staining in aorta of
891int-CAT transgenic mice. (D, F, H, J) CAT
staining in aorta of 891int-CAT (D), 123int-
CAT (F), 891intDBH-CAT (H), and 891int
D0-CAT (J) transgenic mice (original magni-
fication 3100).
Fig. 3. Immunostaining for SMaA and CAT
in cultured mesangial cells derived from trans-
genic mice. (A) SMaA staining in cultured
mesangial cells from 891int-CAT transgenic
mice. (B–E) CAT staining in cultured mesan-
gial cells from wild-type BDF1 mice (B),
891int-CAT (C), 123int-CAT (D), 891intDBH-
CAT (E), and 891intD0-CAT (F) transgenic
mice (original magnification 3100).
Fig. 7. Immunostaining for SMaA and CAT
in the glomerular lesions of Habu venom–
induced glomerulonephritis mice. SMaA (A
and C) and CAT (B and D) were examined
in the consecutive sections from the kidneys
of 891int-CAT (A and B) and 891intD0-CAT
(C and D) transgenic mice eight days after the
intravenous injection of Habu venom (original
magnification 3400).
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Fig. 4. CAT activities in mesangial cells derived from SMaA-promoter
transgenic mice. Two independent lines of each strain were tested.
Fig. 6. In vitro transient transfection analysis of SMaA-promoter ac-Enzyme activities are shown in arbitrary units/mg protein. Values are
tivities in mesangial cells. Assays were performed 48 hours after trans-expressed as mean 6 sd from three different cultures.
fection. The variance in transfection efficiency was monitored and nor-
malized by the luciferase activity from the cotransfected pGV-P2
expression vector. CAT activity was expressed relative to values ob-
tained with the 891int-CAT.
sity of the PCR product was the strongest in 891int-CAT
followed by 123int-CAT. Only trace levels were seen in
mesangial cells from transgenic mice with a deletion in
intron 1, which is consistent with the results of CAT
activity. These results demonstrate that the region from
Fig. 5. RT-PCR detection of CAT (top) and GAPDH (bottom) in 2123 to 13828 is necessary for transcriptional activation
cultured mesangial cells derived from transgenic mice. RNA samples of SMaA during mesangial cell activation in vitro. Infrom wild-type BDF1 mice (lane 1), 891int-CAT (lane 2), 123int-CAT
addition, the 59 upstream region from 2891 to 2124(lane 3), 891intDBH-CAT (lane 4), and 891intD0-CAT (lane 5).
was shown to promote SMaA transcription in cultured
mesangial cells derived from transgenic mice. The region
in intron 1 from 11088 to 11224 is required for efficientexplantation of isolated glomeruli. The glomerulus is
activation of the SMaA promoter in cultured mesangialplaced in the middle of each photograph, and the out-
cells derived from transgenic mice.growth of SMaA-positive mesangial cells from a glomer-
ulus is shown in Figure 3A. Mesangial cells obtained Analysis of transcriptional activity of different
from wild-type BDF1 mice did not show positive staining promoter regions in a transient transfection assay in
for CAT, demonstrating the specificity of the antibody cultured mesangial cells derived from wild-type
(Fig. 3B). Immunostaining demonstrated that mesangial
BDF1 mice
cells derived from 891int-CAT and 123int-CAT strains
The pivotal role of intron 1 for SMaA transcription inwere positive for CAT (Fig. 3 C, D), whereas mesangial
activated mesangial cells was demonstrated in transgeniccells derived from 891intDBH-CAT or 891intD0-CAT
mice. There have been no reports of transcriptional activ-strains did not show detectable levels of CAT protein
ity of promoter regions containing intron 1 in mesangial(Fig. 3 E, F).
cells by in vitro transient transfection analysis. We exam-To analyze CAT expression quantitatively, enzymatic
ined promoter activities of various SMaA promoter-activities of CAT were measured (Fig. 4). Two lines of
CAT fusion genes in transgenic mice by a transient trans-each strain were tested. Strong CAT activity was de-
fection assay in mesangial cells obtained from wild-typetected in 891int-CAT–derived mesangial cells, followed
BDF1 mice (Fig. 6). The highest transcriptional activityby 123int-CAT. There was a 4- to 10-fold difference in
was observed in 2123 to 11, the core promoter region.CAT activities between 891int-CAT– and 123int-CAT–
There was an increase in CAT activity when the 59 up-derived mesangial cells. Marginal CAT activities were
stream region adjacent to the core promoter (2891 toobserved in mesangial cells derived from 891intDBH-
2124) was deleted with or without intron 1 in the pro-CAT or 891intD0-CAT. CAT mRNA in mesangial cells
was confirmed by RT-PCR analysis (Fig. 5). The inten- moter region. Thus, the region from 2891 to 2124 is
Kawada et al: Transcriptional regulation of a-actin 2345
likely to have a negative effect on SMaA transcription at 11088 to 11224, is essential for high transcriptional
activation of SMaA in both cultured mesangial cells de-by in vitro transfection analysis. These results agree with
previous reports by us and others [16–21]. CAT activities rived from transgenic mice and in vivo-activated mesan-
gial cells, and (c) the region from 2891 to 2124 fostersdriven by the promoter region of 891intDBH or 891intD0,
both of which had little transcriptional activity in transcriptional activation of the SMaA promoter in cul-
tured mesangial cells from transgenic mice.transgenic mice, were the same or higher than for 891int
or 123int, a sharp contrast to the results in transgenic The most striking observation of this study is that the
SMaA gene intron 1 plays a significant role in transcrip-mice. These results suggest a negative role for intron 1
in transient transfection. tional activation of SMaA in activated mesangial cells.
We found a dramatic decrease in CAT activities in
Analysis of in vivo transcriptional activation of the 891intDBH-CAT transgenic mice in both smooth muscle
SMaA promoter in activated mesangial cells in cells and activated mesangial cells compared with the
experimental proliferative glomerulonephritis high CAT activities in 891int-CAT transgenic mice.
However, the copy numbers of DBH strains were lowerTo test transcriptional activation of the SMaA pro-
moter in activated mesangial cells in vivo, habu snake than 891int strains, and it was possible that the difference
of copy numbers affected the results. In intron 1 of thevenom-induced GN was induced in transgenic mice. Two
strains of transgenic mice, 891int-CAT and 891intD0- SMaA gene, there is one region where the sequence is
highly conserved among species [18]. To investigate theCAT, were chosen for in vivo analysis, based on the
previously mentioned results of promoter activation. importance of this locus, we deleted a small portion
(11088 to 11224) spanning this well-conserved regionEight days after infusion of habu venom, kidneys were
analyzed by morphologic examination and immunohis- (Fig. 8) and produced transgenic mice (891intD0-CAT).
As expected, activities of CAT were undetectable in bothtochemistry for SMaA and CAT. Glomerular lesions
were assessed by mesangial hypercellularity and matrix in vivo smooth muscle cells and activated mesangial cells
of this strain. The results obtained from 891D0 strainexpansion on hematoxylin eosin-stained sections (data
with regard to the importance of intron 1 (11088 tonot shown). Proliferative GN was observed in both
11224) are thought to overcome the weakness of lowerstrains of transgenic mice (891int-CAT and 891intD0-
copy numbers of 891DBH, as mentioned earlier here.CAT), and intense immunostaining for SMaA was dem-
The region (11088 to 11224) contains the CArG motifonstrated (Fig. 7 A, C). Intraglomerular CAT immuno-
(11098), named as CArG #0. The CArG motifs, charac-staining in 891int-CAT showed a similar distribution to
terized by the consensus sequence CC(A/T-rich)6GG,that of SMaA (Fig. 7B), indicating that the promoter
were first identified in the upstream regions of immedi-region from 2891 to 13814 confers transcriptional acti-
ate-early genes and work as a binding site for SRF [33].vation of SMaA in in vivo mesangial cell activation.
The CArG motif is also present in the upstream regionsDeletion of the 137 bp region in intron 1 from the 891int-
of skeletal, cardiac, and smooth muscle-specific genesCAT resulted in a reduction of CAT expression to unde-
[34]. In cooperation with other muscle-specific cis ele-tectable levels (Fig. 7D).
ments, the CArG motif contributes to muscle-specific
transcriptional activation of these genes. Enhanced ex-
DISCUSSION pression of contractile-related proteins is a characteristic
Smooth muscle a-actin is an excellent marker of acti- of activated mesangial cells. These facts suggest an im-
vated mesangial cells. This study provides new informa- portant role for CArG in the phenotypic modulation of
tion about transcriptional regulation of SMaA. Our re- mesangial cells. Indeed, in the transcriptional regulation
sults highlight the difference in transcriptional regulation of SMaA in cultured mesangial cells, the importance of
of SMaA that occurs between transiently transfected two CArG motifs, CArG #1 (262) and CArG #2 (2112),
cultured mesangial cells and mesangial cells derived from has been described by in vitro promoter analysis [21].
transgenic mice. Transcriptional activation of the re- Some CArG motifs are binding loci for SRF; however,
porter gene CAT was measured in cultured mesangial SRF is a ubiquitously expressed transcription factor, and
cells from transgenic mice and in experimental mesangial it has been suggested that SRF alone is not sufficient to
proliferative GN. These results suggest a complex regula- explain the functional diversity of CArG motifs. Accu-
tory mechanism for transcription of SMaA in activated mulated evidence suggests that the multiplicity of CArG-
mesangial cells. Novel findings are as follows: (a) The dependent gene regulation is produced by post-transla-
region from 2891 to 13828 (containing exon 1, intron tional modification of SRF, by interaction of SRF with
1, and the first 14 bp of exon 2) causes transcriptional SRF-binding proteins, and by a combination with other
activation of SMaA in both cultured mesangial cells from trans-factors that bind cis elements around the CArG
transgenic mice and in vivo activated mesangial cells motif. Understanding CArG-dependent transcriptional
activation of SMaA in activated mesangial cells mayfrom experimental GN. (b) Intron 1, especially the locus
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Fig. 8. Sequence comparison of SMaA gene
intron 1 of human, mouse, and chicken. Se-
quences conserved between at least two of the
depicted species are boxed. CArG #0 is 100%
conserved in human, mouse, and chicken.
Arrows indicate the region of the 137 bp dele-
tion in 891intD0-CAT transgene.
uncover the molecular mechanisms for phenotypic mod- investigation of the role of p53 in activated mesangial
cells may contribute to our understanding of GN. Inulation of mesangial cells. The functions of the “core
promoter” region are reported, but little is known about regions 2257 to 2189 and 2151 to 2123, smooth muscle-
specific positive elements may exist [20, 27].the functional role of the CArG motif in intron 1. Future
investigation of intron 1, especially the region around The mechanism of differential regulation of the SMaA
promoter between transient transfection using wild-typeCArG #0, may provide a better understanding of the
molecular mechanisms of transcriptional activation of mesangial cells and mesangial cells derived from
transgenic mice is not clear. We attempted to determineSMaA in activated mesangial cells and their role in glo-
merular disease. whether differences in cell passage influenced the tran-
scriptional activities of the SMaA promoter in mesangialAnother important observation is that the SMaA gene
from 2891 to 2124 contains positive elements for tran- cells derived from transgenic mice. However, there were
no substantial changes in CAT activities through sevenscriptional activation of SMaA in activated mesangial
cells derived from transgenic mice. Because of the nega- passages (data not shown). Another possible reason for
differential regulation is the status of transfection, stabletive effects of this region on SMaA transcription, as
demonstrated by in vitro transient transfection studies versus transient. Of note, in the previous study, we
showed that the sequence (1972/11152) in intron 1 has[20, 21], little attention has been paid to the regulatory
role of this region in the transcriptional activation of an enhancer activity under the artificial condition when
this sequence was fused to SV40 promoter [18]. In thisSMaA in activated mesangial cells. However, this region
contains several interesting elements. One M-CAT–like study, we studied the effect of the authentic intron 1
sequence for the first time and found that the regionelement is located at 2178 [26]. Mar and Ordahl revealed
that TGF-b–mediated activation of the skeletal a-actin (11088/11224) plays a significant role for the in vivo
study. The positive effect of intron 1 was not detectedgene was dependent on an M-CAT site, which binds
members of the transcriptional enhancer factor-1 family in in vitro study. The result of previous in vitro studies
seems opposite to present in vitro study. However, as[35]. TGF-b promotes phenotypic modulation of cells to
myofibroblasts in a variety of tissues [36], and TGF-b is discussed in a previous study, we are considering that in
natural chromatin structure, the intron 1 might be lo-induced in glomeruli in in vivo GN [37]. Inhibition of
the TGF-b action has beneficial effects on glomeruloscle- cated in close proximity to the promoter region and
might work as an enhancer. In in vitro study, transgenerosis and phenotypic modulation of mesangial cells [38,
39]. In addition, Hautmann, Madsen, and Owens re- cannot integrate into genome or form chromatin struc-
ture, and, thus, the status of transgene, in chromatin orcently found a TGF-b control element in the SMaA
core promoter region at 242 [22]. These data support a not, may influence the differential result of in vivo and
in vitro. Although more precise investigations are neces-significant role for TGF-b in the phenotypic modulation
of mesangial cells in the pathogenesis of GN. sary, this study suggests the limitations of in vitro tran-
sient transfection analysis.Another interesting element in this region is a p53-
responsive element located at 2312 to 2291 [25]. p53 is In conclusion, in vivo promoter analysis of the SMaA
gene provides new information about the transcriptionalan important tumor suppressor; alterations in p53 are
common in human tumors [40]. The functions of p53 regulation of SMaA in activated mesangial cells. The
DNA region 2891 to 2124 has a positive effect onare to arrest cell cycle progression and induction of cell
death. Enhanced glomerular expression of p53, espe- SMaA transcription in cultured mesangial cells. The in-
tron 1 region, including the CArG motif, plays a pivotalcially in proliferative lesions, has been reported in human
glomerular diseases such as IgA nephropathy, focal glo- role in SMaA transcription in activated mesangial cells
in vivo. Further analysis of this conserved region in intronmerular sclerosis, and lupus nephritis [41, 42]. Further
Kawada et al: Transcriptional regulation of a-actin 2347
segment containing an evolutionarily conserved motif is required1 will be of great value in understanding the molecular
in cis for cell-type-restricted repression of the chicken a-smooth
mechanisms of mesangial activation. muscle actin gene core promoter. Mol Cell Biol 8:241–250, 1988
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